40results about How to "Stable expression" patented technology

The invention discloses preparation of an antibody capable of detecting multi-subtype KPC and application of a kit of the antibody, and belongs to the field of biological medicine. According to the kit for detecting the common subtypes of KPC and the application of the kit, the mouse antibodies are prepared through immunization of conserved antigen epitopes of all the subtypes of KPC, in-vitro screening and pairing are carried out in multiple modes, then an antibody pair which is good in specificity and high in affinity and can be combined with multiple subtypes is obtained, the titer of the two antibodies can reach one million or above, and the kit is high in specificity, good in affinity and capable of being used for detecting the common subtypes of KPC. Amino acid sequences of a heavy chain variable region and a light chain variable region are obtained through sequencing, and rapid and stable expression can be realized after recombination. The product for detecting the carbapenem KPC is developed on the basis of an immunochromatography platform, and the kit has the advantages of high sensitivity, good specificity, good stability, capability of covering most epidemic KPC subtypes and rapidness and convenience in detection, and provides important help for clinical auxiliary diagnosis and medication guidance.

The present invention relates to a respiratory syncytial virus subtype B (RSV-B) recombinant F protein, a polynucleotide encoding the same, a nucleic acid construct comprising the polynucleotide, an expression vector comprising the nucleic acid construct, a host cell wherein the polynucleotide, the nucleic acid construct or the expression vector is transformed or transfected, a stabilized trimer formed therefrom, and a method for preparing the same. An immunogenic composition comprising any of the foregoing, and its use in the preparation of a vaccine for the prevention and / or treatment of respiratory syncytial virus infection. The RSV-B recombinant F protein comprises at least one specific epitope of the pre-fusion F protein, a stable F protein tripolymer with pre-fusion conformation can be formed, the expression is stable, the form is uniform, and the yield is greatly improved; the formed F protein trimer has good immunogenicity, can stimulate an organism to generate high-level antibody titer, and has great significance in clinical treatment and prevention and control of the respiratory syncytial virus.

The invention provides an application of a mesenchymal stem cell modified by an IGF-1 (Insulin-like Growth Factor 1) gene in treatment of premature ovarian failure. The invention provides a modified IGF-1mRNA (Insulin-like Growth Factor). The modified IGF-1mRNA comprises a 5'end capping structure (Cap) and a 3 '-polyA tailed structure of an RNA (Ribonucleic Acid) sequence, and encapsulating the modified IGF-1 mRNA (messenger Ribonucleic Acid) by using an ionizable lipid. The invention further provides a preparation method of the liposome based on the ionizable lipid, a method for improving the transfection efficiency of the IGF-1 in-vitro transfected mesenchymal stem cells and the IGF-1 transfected mesenchymal stem cells obtained by adopting the method, MSCs are promoted to continuously and stably express IGF-1, the MSCs can stably secrete factors to promote cell proliferation and differentiation, and the granular cell secretion activity is maintained. The IGF-1 transfected mesenchymal stem cells can be used for preparing a medicine for treating premature ovarian failure, the IGF-1 modified MSCs can assist the premature ovarian failure in recovery, and the technical problem that the treatment effect cannot be improved due to the fact that the dosage of the MSCs is limited in the clinical treatment process can be solved.

Provided is a fully human single-domain tandem chimeric antigen receptor (CAR) capable of specifically binding to a CD5 protein, which comprises a CDS binding domain, a transmembrane domain, a co-stimulatory domain and an intracellular signaling domain. Also provided are engineered immune effector cells, such as T cells, comprising the chimeric antigen receptor, and use of the CAR and the engineered immune effector cells in the treatment of diseases or conditions associated with the expression of CD5.

The invention belongs to the technical field of genetic engineering, and particularly relates to recombinant hydroxylated human III-type collagen as well as a preparation method and application thereof. The invention relates to a recombinant hydroxylated human III-type collagen with cell adhesion. The amino acid sequence of the recombinant hydroxylated human III-type collagen is shown as SEQ ID NO. 1. Nine different sites of the full-length natural III-type collagen are replaced, four natural integrin sites with low adhesion are replaced under the condition that the total length of natural full-length amino acid is not changed, and meanwhile, terminal peptide is reserved, so that the collagen has the potential of forming a triple helix structure. According to the modification mode, the adhesion of the collagen is improved by 27% or above, the molecular weight of the collagen is moderate, the collagen is easy to prepare, and hydroxylation enables the collagen to be expressed more stably.

The present invention relates to the field of gene engineering technology, and in particular to the application of a rice seed storage gene OsNBS2 linked molecular marker in identifying storage-resistant rice varieties. The rice seed storage gene OsNBS2 linked molecular marker is used in identifying storage-resistant rice varieties. The rice seed storage gene OsNBS2 linked molecular marker is located at Chr 6:10438484 in the exon region of the rice OsNBS2 gene, and the storage-intolerant rice variety lacks the base G. The rice seed storage gene obtained by the present invention can be stably expressed in different genetic generations and has high reliability. The molecular marker of the present invention can be used for the identification and selection of rice seedling genotypes, and individuals carrying excellent natural allele variations of seed storage genes can be obtained, which can overcome the shortcomings of conventional breeding methods such as a long time period, difficulty in phenotypic identification, and poor repeatability, and accelerate the breeding process of new varieties of highly storage-resistant rice.

This invention relates to the field of natural language processing technology, and more particularly to a method and system for language transfer recognition based on cultural semantic embedding. The method includes the following steps: acquiring source language data and target language data; performing semantic isomorphic centering on the source and target language data to obtain semantically equivalent data; decoupling pragmatic features based on the semantically equivalent data to obtain pragmatic feature data; performing contrastive cultural latent space embedding based on the pragmatic feature data to obtain bilateral cultural representation data; performing cultural modality affine transformation based on the bilateral cultural representation data to obtain cultural difference data; performing implicit distortion pattern discrimination based on the cultural difference data to obtain cultural semantic distortion data; and generating transfer results based on the cultural semantic distortion data to obtain language transfer result data. This invention decouples pragmatic features under semantic equivalence constraints and achieves language transfer recognition through cultural semantic embedding and modality affine modeling.

The invention belongs to the technical field of alginate lyase preparation, and particularly relates to truncated alginate lyase MHALY-T as well as a preparation method and application thereof. The invention provides truncated alginate lyase MHALY-T, and the nucleotide sequence of the truncated alginate lyase MHALY-T is as shown in SEQ ID NO. 2. The obtained alginate lyase has high hydrolytic activity on sodium alginate, the crude enzyme liquid generated through shake flask fermentation has the capacity of degrading 10 g of sodium alginate through 1 mL of crude enzyme liquid (the protein content is about 0.23 mg), and the alginate lyase has the application potential of large-scale preparation of alginate oligosaccharide and has good industrial application prospects.

The invention discloses an intestinal bacterium-derived melatonin synthetase and an application thereof. Specifically, the melatonin synthetase is selected from one or more of a DDC enzyme, an AANAT enzyme and an AST enzyme, the DDC enzyme comprises an amino acid sequence as shown in SEQ ID NO.2 or an active fragment of the amino acid sequence, or an analogue of which the similarity with the amino acid sequence as shown in SEQ ID NO.2 is more than 80%, and the DDC enzyme comprises an amino acid sequence as shown in SEQ ID NO.2 or an active fragment of the amino acid sequence as shown in SEQ ID NO.2 or an analogue of which the similarity with the amino acid sequence as shown in SEQ ID NO.2 is more than 80%. The AANAT enzyme comprises an amino acid sequence as shown in SEQ ID NO.34 or an active fragment thereof, or an analogue of which the similarity with the amino acid sequence as shown in SEQ ID NO.34 is more than 80%, and the AST enzyme comprises an amino acid sequence as shown in SEQ ID NO.42 or an active fragment thereof, or an analogue of which the similarity with the amino acid sequence as shown in SEQ ID NO.42 is more than 80%. On one hand, the melatonin synthetase can be used for improving the melatonin level of a host and improving related diseases; on the other hand, the method can be used for biosynthesis of melatonin and has a good application prospect.

The present invention discloses a SINV infectious vector and its application in the preparation of anti-tumor drugs, wherein the SINV infectious vector uses pSINV as a backbone vector, and granulocyte-macrophage colony stimulating factor GM-CSF is connected to the backbone vector. The SINV infectious vector of the present invention can more stably express the inserted exogenous gene, and the biological characteristics of the virus are not significantly different from those of the wild type; the SINV virus particles of the present invention can replicate in cervical cancer Hela tumor cells and liver cancer Hep3B tumor cells, selectively infect tumor cells, and achieve a killing effect on tumors in an immunodeficient mouse model, which has important practical significance and wide application value for applied research and basic research such as oncolytic treatment of cervical cancer and liver cancer.

The invention discloses an immortalized goat placenta trophoblast cell line and a construction method thereof, and relates to the technical field of cell engineering. The construction method comprises the following steps: carrying out isolated culture by using a tissue block culture method to obtain primary goat placenta trophoblast cells; eukaryotic expression plasmids pCI-neo-hTERT are introduced into the primary goat placenta trophoblast cells, positive clones are obtained through screening, subculture is carried out to 80 generations, and the immortalized goat placenta trophoblast cell line is obtained. The genetic structure of the immortalized goat placenta trophoblast cell line constructed by using the construction method can be kept stable in an infinite passage process, and when the immortalized goat placenta trophoblast cell line is transferred to 80 generations, the number of chromosomes is still 60, and the chromosomes are not lost or doubled. Transwell and RT-PCR detection prove that the immortalized goat placenta trophoblast cell line has an invasion characteristic, and TERT protein is stably expressed in the immortalized goat placenta trophoblast cell line.

The invention relates to the technical field of biological pathology detection, and particularly discloses a tumor tissue PD-L1 gradient quality control sheet as well as a preparation method and application thereof. The tumor tissue PD-L1 gradient quality control sheet comprises a slide label area, a staining control area and a tissue patch area, three HIS-PDTX tumor living tissues or hPBMC-PDTX tumor living tissue samples which play a control role and have the PD-L1 staining gradient being negative, the PD-L1 staining gradient being medium expression and the PD-L1 staining gradient being high expression are fixed in the staining control area, and the HIS-PDTX tumor living tissue samples are fixed in the tissue patch area. Meanwhile, traceability and continuous supply of sample sources are ensured; the samples can accurately reflect the distribution condition of PD-L1 in HIS-PDTX tumor living tissue or hPBMC-PDTX tumor living tissue structures, and the accuracy and reliability of the tumor tissue PD-L1 gradient quality control wafer can be improved by using the samples as control.

The invention discloses a DNA structure for saccharomyces cerevisiae single-cell barcode labeling and chromatin state conjoint analysis and application thereof, and belongs to the technical field of molecular biology and single-cell multi-omics analysis. From the 5'end to the 3 'end, a fluorescent protein gene, a Tn5ME structure, a reverse transcription primer binding region, a CYC1 terminator fragment and a linearized shuttle plasmid skeleton are subjected to homologous recombination, and a pCM carrier is obtained; after NdeI / BamHI enzyme digestion, oligonucleotides with random sequences, which are subjected to annealing, amplification, Klenow filling-in and enzyme digestion, are connected, and transformation extraction is carried out, so that the DNA structure for saccharomyces cerevisiae single-cell barcode labeling and chromatin state combined analysis is obtained. On the basis of the constructed DNA structure, ATAC-seq and a bar code reverse transcription method are combined, important data related to the transcription state and chromatin state of a single cell can be obtained at the same time through bar code information, single cell pedigree tracking of the saccharomyces cerevisiae is achieved, and research on single cell epigenomics of the saccharomyces cerevisiae and other microorganisms is promoted.

The invention discloses a method for knocking down or overexpressing a PDK4 gene of a BV2 microglial cell by utilizing a lentivirus technology and application of the method in ferroptosis research, and relates to the technical field of molecular biology and cytobiology, and the method comprises the following steps: designing an shRNA sequence through a full-length sequence of the PDK4 gene of a mouse so as to realize gene knocking down, or designing a cDNA sequence so as to carry out gene overexpression; the method comprises the following steps: constructing a lentiviral vector containing an shRNA sequence or a cDNA sequence, wherein the vector carries green fluorescent protein (GFP) and a purinase resistance gene; then carrying out lentivirus packaging and purification; the BV2 microglial cells are obtained and cultured; bV2 microglial cells are infected by lentivirus, and the BV2 microglial cell strain with stable knock-down or stable overexpression of the PDK4 gene is obtained through puromycin screening. According to the scheme, the cell strain capable of stably expressing PDK4 can be obtained, and the effect of the cell strain in ferroptosis is systematically researched.

A plasmid platform according to the present invention comprises a nucleic acid sequence encoding a modified protein from which an intracellular domain, an extracellular domain, or a combination thereof of lysosome-associated membrane glycoprotein 2B (LAMP-2B) has been removed, and is based on the discovery that removing a specific domain of LAMP-2B significantly stabilizes the expression of intended biomolecules and significantly increases the efficiency with which intended biomolecules are delivered. The plasmid platform is expected to provide high technical utility in the expression and delivery of proteins of interest, particularly expression and delivery using exosomes, and may be expanded to various associated technical fields or uses.

The present invention provides a tuberculosis subunit vaccine, which comprises a fusion protein LT33, a fusion protein LT28 and an adjuvant; the fusion protein LT33 is prepared by sequentially connecting ESAT6, CFP10 and Rv1738; the fusion protein LT28 is prepared by sequentially connecting MPT64 61‑170 、Rv1978 8‑60 and Rv2645 21‑80 The invention also provides a preparation method thereof. The tuberculosis subunit vaccine of the invention can effectively induce tuberculosis antigen-specific cellular and humoral immune responses in mice, and at the same time, the vaccine can mediate the protection of mice against Mycobacterium tuberculosis H37Rv infection. The vaccine is expected to become a new type of tuberculosis subunit vaccine. It has good application development prospects.

The invention relates to the technical field of synthetic biology, and discloses a copy number regulation and control system based on a 2 mu plasmid, the copy number regulation and control system comprises a plasmid with a controllable copy number and an expression system thereof, and the regulation and control method comprises the following steps: S1, inserting an endogenous protein sequence driven and expressed by promoters with different intensities into a genome of a saccharomyces cerevisiae cell or the plasmid; s2, the saccharomyces cerevisiae cells or the plasmids express endogenous proteins with different intensities; s3, transferring a 2 mu plasmid without the endogenous protein sequence; and S4, finishing the copy number regulation and control of the 2 mu plasmid. According to the method, the copy number of the plasmid is changed and the range of the copy number is expanded by artificially modifying the expression quantity of the replication isolated protein of the endogenous 2mu plasmid, and an antibiotic or an inducer does not need to be added, so that the culture cost is greatly reduced, and the growth speed of the strain is almost not influenced.

This invention relates to the use of a gene carrier as a drug delivery carrier, the gene carrier comprising metal nanoparticles and a double-stranded nucleic acid molecule bound to the surface of the metal nanoparticles. The invention particularly relates to the use of the carrier for treating metabolic diseases, and to pharmaceutical compositions for the prevention or treatment of metabolic diseases, the pharmaceutical compositions comprising the carrier.

The invention belongs to the technical field of bioengineering, and particularly relates to recombinant lactobacillus plantarum as well as a construction method and application thereof in resisting porcine epidemic diarrhea. According to the invention, by constructing a lactobacillus plantarum gene editing plasmid, the S1 protein of the PEDV LJX01 strain is integrated into a lactobacillus plantarum WCFS1 genome, so that stable passage of a virus gene sequence is realized, immunogenicity is expected to be enhanced, an organism is induced to generate stronger immune response, PEDV infection is effectively resisted, and the problem of poor immune effect of a traditional vaccine is solved.

The invention provides a sea urchin globosus macrophage migration inhibition factor polyclonal antibody, an antigen protein and a preparation method thereof, and belongs to the technical field of antibody preparation. According to the invention, the coding gene and the recombinant expression vector of the sea urchin MIF antigen protein are successfully obtained, and the sea urchin MIF antigen protein can be prepared by the method provided by the invention; after Kunming mice are immunized with the obtained sea urchin globosus MIF antigen protein, the sea urchin globosus MIF polyclonal antibody is successfully obtained, the problem that in the prior art, a sea urchin globosus MIF antibody is lacked is solved, and a meaningful tool and experimental support are provided for biological function research of sea urchin MIF. The invention further provides a gene sequence for coding the sea urchin globosus MIF, the complete sequence of the gene coding region of the MIF can be successfully amplified through the primer provided by the invention, and the blank of related research is filled.

The invention relates to an enzymatic synthesis method of glutamine dipeptide, and belongs to the technical field of biosynthesis. In order to solve the problem of poor purity in the prior art, the invention provides an enzymatic synthesis method of N-(2)-L-alanyl-L-glutamine dipeptide, which is characterized by comprising the following steps: reacting L-glutamine with L-alanine methyl ester to obtain N-(2)-L-glutamine dipeptide by using alpha-ester acyltransferase which does not have signal peptide and has an amino acid sequence as shown in SEQ ID NO.1 or SEQ ID NO.3. The invention also provides an enzymatic synthesis method of N-(2)-L-glutamine dipeptide. The L-glutamine and L-alanine methyl ester can be effectively promoted to react so as to be converted into the L-glutamine dipeptide, the enzyme activity is high, the selectivity is high, the purity reaches 99% or above, and the yield reaches 80% or above.

The present invention belongs to the field of biotechnology, and specifically relates to the application of ISG15-(H4)2-IFN-λ3 recombinant protein in the preparation of drugs for preventing and treating PRRSV infection. The present invention selects (H4)2 connecting peptide to connect ISG15 and IFN-λ3 to prepare ISG15-(H4)2-IFN-λ3 recombinant protein, which can achieve stable and large-scale expression of IFN-λ3 protein, solves the technical problem that IFN-λ3 cannot be mass-produced using a prokaryotic expression system, and at the same time, the present invention verifies the anti-PRRSV activity of ISG15-(H4)2-IFN-λ3 recombinant protein in vivo, proving that the recombinantly expressed ISG15-(H4)2-IFN-λ3 recombinant protein has an inhibitory effect on inhibiting the replication of PRRSV in vivo, reduces the secretion of inflammatory factors in the lungs and improves the viremia caused by PRRSV infection.

The invention relates to the field of disease resistance identification of pepper vein mottle viruses, and particularly discloses a method for inserting a GFP large protein into pCB301-ChiVMV and application of the method in disease resistance identification of the pepper vein mottle viruses, and a constructed fusion vector has the advantages that (1) the fusion vector has infectivity, and the infectivity of the ChiVMV on a host is not influenced after a GFP foreign protein sequence is introduced; and (2) the GFP protein can be stably expressed in nicotiana benthamiana and pepper. On the basis, the method can be used for inoculating a pepper material, and the resistance of the pepper to be detected can be evaluated by observing fluorescence and calculating the morbidity, disease index and resistance index. The efficient infection and expression of ChiVMV and GFP proteins in the pepper are realized, and the step of purifying the virus for identification is simplified; the resistance condition of a host to a single virus can be accurately identified; the method can accurately observe the morbidity of the pepper through green fluorescence, is suitable for batch development of pepper resistance identification, saves manpower and material resources, and improves the accuracy and reliability of resistance identification.

The application provides a construction method and application of recombinant escherichia coli for efficiently preparing high-purity sialyllactose-N-tetraose a. The application precisely integrates genes encoding beta-1,3-N-acetylglucosamine glycosyltransferase, beta-1,3-galactosyltransferase and alpha-2,3-sialic acid glycosyltransferase in the genome of escherichia coli BL21 (DE3), knocks out endogenous competitive metabolic genes, and optimizes the metabolic pathways of precursor substances UDP-acetylglucosamine, UDP-galactose and CMP-N-acetylneuraminic acid, effectively reduces the generation of non-target byproducts including lactose-N-triose, lactose-N-tetraose and 3'-sialyllactose, and successfully constructs a recombinant chassis strain capable of efficiently producing high-purity sialyllactose-N-tetraose a. Fermentation culture of the constructed engineering bacteria can efficiently prepare high-purity sialyllactose-N-tetraose a under the premise of guaranteeing biosafety, and is suitable for the production demand in the food field.

A new coronavirus vaccine based on controllable secretory expression of attenuated Salmonella, a preparation method therefor, and use thereof. The method comprises constructing controllable and stable expression plasmids for secretory expression of different antigenic structural domain proteins of the new coronaviruses and their attenuated Salmonella expression strains, and then mixing various attenuated Salmonella antigen-presenting strains that can achieve controllable intracellular secretory expression in antigen-presenting cells. With the aid of a unique secretion system, a variety of different antigenic proteins can be secretory-expressed efficiently in antigen-presenting cells after oral gavaging. The secretory-expressed antigenic proteins can be efficiently processed and presented by the antigen-presenting cells, and finally activate / regulate the immune system to produce more potent antibodies to make the vaccine work.

The invention relates to the technical field of gene therapy, in particular to a method for knocking out a Bax gene on the basis of an HEK293 cell line by utilizing a CRISPR / Cas9 technology, constructing a stable cell line expressed by foreign protein and improving the AAV packaging efficiency. The invention discloses a Bax2.6 cell strain. A pro-apoptosis factor Bax gene is knocked out from an HEK293T cell. Compared with a wild type HEK293T cell, the Bax2.6 cell strain provided by the invention shows higher cell activity under various stress conditions, the cell survival rate of the Bax2.6 cell strain is improved by at least 20% under the treatment conditions of small molecule inhibitors ZV-FMK, Nec-1, puromycin (Puro), cis-platinum (CDDP) and rotenone, and the Bax2.6 cell strain shows excellent environmental tolerance and production robustness. When the Bax2.6 cell strain provided by the invention is used for transient transfection and packaging of an adeno-associated virus (AAV) vector, the copy number of the obtained AAV virus can be up to 2 * 10 copies / mL, and the AAV packaging efficiency is improved by more than 10 times compared with that of a conventional HEK293T cell line.

The invention belongs to the technical field of microorganisms, and particularly relates to application of schizophyllum commune ergothioneine synthetase genes ScEgt1a and ScEgt2b in synthesis of ergothioneine, and the ergothioneine synthetase genes ScEgt1a and ScEgt2b are obtained by finding out the sequences of the ergothioneine synthetase genes ScEgt1a and ScEgt2b in genome annotation of schizophyllum commune, performing codon optimization and then utilizing a direct synthesis method. The obtained ergothioneine synthase genes ScEgt1a and ScEgt2b are utilized to construct an engineering vector for starting efficient expression of the ergothioneine synthase genes ScEgt1a and ScEgt2b by using a pichia pastoris promoter pGCW14, the engineering vector is transformed and integrated into a pichia pastoris X33 genome, and a recombinant engineering strain for high yield of ergothioneine is obtained through screening; by optimizing the culture medium composition and fermentation conditions, under the optimal conditions, the recombinant pichia pastoris engineering bacteria are subjected to shake-flask fermentation for 96 hours, the yield of ergothioneine reaches 1.67 g / L, and the method has industrial production prospects.

The application discloses a recombinant herpesvirus of turkeys co-expressing classic strains and variant strains of IBDV VP2 and a construction method and application thereof, and belongs to the field of veterinary biological technology. The recombinant virus has good genetic stability, and has a consistent replication rate with HVT vaccine viruses in vitro. When used as a vaccine, 1-day-old chicks can be clinically protected against vvIBDV and nVarIBDV at 100% after single immunization, can induce the body to produce high-titer specific antibodies, protect the immune organs of chickens from virus invasion, and has a broad industrial application prospect in the preparation of IBDV multivalent vaccines.

The invention relates to the field of biological medicine, in particular to an NY-ESO-1 specific TCR-T receptor and application thereof. The genome of the NY-ESO-1 specific TCR-T receptor comprises an alpha-chain constant region gene and a beta-chain constant region gene of a human T cell receptor alpha95: LY subjected to murine transformation, and the amino acid sequences of the alpha-chain constant region gene and the beta-chain constant region gene are respectively shown as SEQ ID NO.8 and SEQ ID NO.10. The NY-ESO-1 specific TCR-T receptor comprises an alpha chain as shown in an amino acid sequence of SEQ ID NO: 4 and a beta chain as shown in an amino acid sequence of SEQ ID NO: 6. The TCR expression efficiency and stability of the NY-ESO-1 specific TCR-T receptor are greatly improved, the effectiveness and safety of in-vivo application of the NY-ESO-1 specific TCR-T receptor are promoted, and the NY-ESO-1 specific TCR-T receptor is simple and easy to design, has high reference value for TCR-T preparation and application and is suitable for popularization and application.

The application provides a fusion protein for antibody site-specific coupling and application thereof. The fusion protein of the application is mainly fused by an antibody Fc affinity protein binding monomer and an avidin protein, realizes direct coupling of the antibody Fc affinity protein and a biotin-labeled molecule, and no longer uses a click chemistry scheme, so that the production and use difficulty of the antibody Fc affinity protein Protein G is greatly simplified, the Protein G protein no longer needs to be activated through the click chemistry in the production, the transportation and storage conditions no longer need to be strictly controlled, and even one-step antibody molecule coupling can be realized.